Abstract

Emerging studies indicate that APOA-I binding protein (AIBP) is a secreted protein and functions extracellularly to promote cellular cholesterol efflux, thereby disrupting lipid rafts on the plasma membrane. AIBP is also present in the mitochondria and acts as an epimerase, facilitating the repair of dysfunctional hydrated NAD(P)H, known as NAD(P)H(X). Importantly, AIBP deficiency contributes to lethal neurometabolic disorder, reminiscent of the Leigh syndrome in humans. Whereas cyclic NADPHX production is proposed to be the underlying cause, we hypothesize that an unbiased metabolic profiling may: 1) reveal new clues for the lethality, e.g., changes of mitochondrial metabolites., and 2) identify metabolites associated with new AIBP functions. To this end, we performed unbiased and profound metabolic studies of plasma obtained from adult AIBP knockout mice and control littermates of both genders. Our systemic metabolite profiling, encompassing 9 super pathways, identified a total of 640 compounds. Our studies demonstrate a surprising sexual dimorphism of metabolites affected by AIBP deletion, with more statistically significant changes in the AIBP knockout female vs male when compared with the corresponding controls. AIBP knockout trends to reduce cholesterol but increase the bile acid precursor 7-HOCA in female but not male. Complex lipids, phospholipids, sphingomyelin and plasmalogens were reduced, while monoacylglycerol, fatty acids and the lipid soluble vitamins E and carotene diol were elevated in AIBP knockout female but not male. NAD metabolites were not significantly different in AIBP knockout vs control mice but differed for male vs female mice. Metabolites associated with glycolysis and the Krebs cycle were unchanged by AIBP knockout. Importantly, polyamine spermidine, critical for many cellular functions including cerebral cortex synapses, was reduced in male but not female AIBP knockout. This is the first report of a systemic metabolite profile of plasma samples from AIBP knockout mice, and provides a metabolic basis for future studies of AIBP regulation of cellular metabolism and the pathophysiological presentation of AIBP deficiency in patients.

Highlights

  • Cellular metabolites serve as the engine to drive distinct cell functions

  • Low et al suggest an alternative mechanism for AIBP regulation of lipid rafts: they reported that AIBP per se, but not cholesterol efflux, modulates lipid raft in macrophages via the cellular cytoskeleton; in this scenario, AIBP binding of PI3P regulates Rho family GTPase CDC42 activation, thereby resulting in cytoskeleton rearrangement and lipid raft disassembly [7]

  • Profound gender effects observed in the AIBP knockout mice

Read more

Summary

Introduction

Cellular metabolites serve as the engine to drive distinct cell functions. Our and other publications have shown that AIBP functions as a critical component of lipid metabolism [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17]. Lipid rafts serve as the critical platform for the clustering and proper function of many plasma membrane receptors, including angiogenic VEGFR2 signaling and TLR4-mediated inflammatory response. Both signaling are repressed by AIBP gain-of-function [2, 4, 5, 9, 12, 13, 17]. We have recently shown that AIBP-mediated cholesterol efflux activates sterol regulatory element binding protein 2 (SREBP2), which in turn transcriptionally upregulates NOTCH1, thereby connecting hematopoiesis and hypercholesterolemia [6]. Low et al suggest an alternative mechanism for AIBP regulation of lipid rafts: they reported that AIBP per se, but not cholesterol efflux, modulates lipid raft in macrophages via the cellular cytoskeleton; in this scenario, AIBP binding of PI3P regulates Rho family GTPase CDC42 activation, thereby resulting in cytoskeleton rearrangement and lipid raft disassembly [7]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.